Core Viewpoint - Zhejiang Haisheng Medical Devices Co., Ltd. is set to go public on the Beijing Stock Exchange, aiming to raise approximately 37 million yuan for the upgrade and expansion of its anesthetic and monitoring medical devices, as well as for the establishment of a research and testing center and a marketing service base [2]. Group 1: Company Overview - The company specializes in the research, production, and sales of anesthetic and monitoring medical devices, which are widely used in departments such as anesthesiology, ICU, and emergency [2]. - Huang Haisheng holds a 47.11% stake in the company, making him the controlling shareholder, while his spouse, Wu Xiaoye, indirectly controls an additional 7.81% through Lixin Investment, resulting in a combined control of 54.92% [2]. Group 2: IPO Details - The company plans to issue shares at a price of 12.64 yuan per share, with an expected earnings per share (EPS) ratio of 13.99, aligning with the specialized equipment manufacturing industry [1]. - The total number of shares to be issued is 11.2941 million, with 10.1647 million shares available for online subscription [1]. - The expected total fundraising amount is 142.7577 million yuan, with a net amount of approximately 113.4382 million yuan after deducting estimated issuance costs of 29.3194 million yuan [2].

Core Viewpoint - The article highlights the significant developments and financial performance of Hainan Baimaike Medical Technology Co., Ltd., including its upcoming IPO and product innovations in the medical device sector [1][9]. Company Overview - Hainan Baimaike Medical Technology Co., Ltd. was established on June 1, 2007, with a registered capital of 40.65 million yuan. The company is headquartered in Ding'an, Hainan Province [2]. - The controlling shareholder is Hainan Maidike Pharmaceutical Holdings Co., Ltd., holding a 48.35% stake [2]. - The company specializes in the research and production of surgical sutures and hemostatic materials, as well as peptide pharmaceutical equipment [4]. Financial Performance - In 2024, Baimaike achieved a revenue of 185 million yuan, representing a year-on-year growth of 6.27%. The net profit attributable to shareholders was 69.19 million yuan, a decrease of 1.41% compared to the previous year. The gross margin improved to 78.8%, up from 75.88% in the prior year [3]. - For the first half of 2024, the company reported a revenue of 78.21 million yuan and a net profit of 29.68 million yuan [3]. Product Innovations - Baimaike's core product, the "Feng Chuang Ling" surgical suture, is the first domestic absorbable suture with barbs, designed for secure tissue anchoring during clinical procedures. The annual usage exceeds one million units, with a market share of 5.8% in China [4]. - The company has launched the world's first gelatin sponge embolization microsphere, "Bai Ji Fu," which offers high elasticity and precise intervention capabilities, breaking the monopoly of foreign giants in this field [6]. - Baimaike ranks fourth in China's knotless suture market, following Johnson & Johnson, Shunke, and Medtronic [8]. Future Developments - The company has completed the construction of a modern factory in Hainan and is preparing for its IPO on the Beijing Stock Exchange, marking its entry into the capital market [9]. - The actual controller, Yang Dingjian, expressed intentions to expand into a full range of medical sutures, aiming to establish a comprehensive and high-tech brand in the medical suture industry [9].